Overall survival by clinical risk category for high dose interleukin-2 (HD IL-2) treated patients with metastatic renal cell cancer (mRCC): data from the PROCLAIMSM registry

by M. Fishman, J. P. Dutcher, J. I. Clark, A. Alva, G. P. Miletello, B. Curti, Neeraj Agarwal, R. Hauke, K. M. Mahoney, H. Moon, J. Treisman, S. S. Tykodi, G. Daniels, M. A. Morse, M. K. K. Wong, H. Kaufman, N. Gregory, D. F. McDermott
Published 2019-03-01